Jonathan Friedberg, MD, University of Rochester, Rochester, NY, outlines future directions in the treatment and management of older patients with Hodgkin lymphoma (HL) including enrollment of this patient population in clinical trials and reducing chemotherapy to mitigate toxicities seen in older patients, for example with the use of checkpoint inhibitors. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.